Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alvotech (ALVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 22.97% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.91B USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 127066 | Beta -0.16 | 52 Weeks Range 9.15 - 14.76 | Updated Date 04/2/2025 |
52 Weeks Range 9.15 - 14.76 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.0273 | Actual -0.24 |
Profitability
Profit Margin -47.13% | Operating Margin (TTM) 9.33% |
Management Effectiveness
Return on Assets (TTM) 4.06% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 44.84 | Enterprise Value 4048214726 | Price to Sales(TTM) 5.91 |
Enterprise Value 4048214726 | Price to Sales(TTM) 5.91 | ||
Enterprise Value to Revenue 8.27 | Enterprise Value to EBITDA -8.78 | Shares Outstanding 301806016 | Shares Floating 106763758 |
Shares Outstanding 301806016 | Shares Floating 106763758 | ||
Percent Insiders 64.81 | Percent Institutions 6.3 |
Analyst Ratings
Rating 4 | Target Price 17.4 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alvotech
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on the development and manufacturing of biosimilar medicines. Founded in 2012, Alvotech aims to be a global leader in biosimilars.
Core Business Areas
- Biosimilar Development: Alvotech focuses on developing biosimilars of complex biologics, targeting autoimmune disorders, oncology, and other therapeutic areas.
- Manufacturing: The company operates a state-of-the-art manufacturing facility in Iceland, producing biosimilars for global markets.
- Commercialization: Alvotech partners with pharmaceutical companies to commercialize its biosimilars worldwide.
Leadership and Structure
Robert Wessman serves as the Executive Chairman. The company is structured with functional teams spanning R&D, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- AVT02 (adalimumab biosimilar): Biosimilar to Humira (adalimumab), used to treat autoimmune diseases. Expected to have significant market share, competing with other adalimumab biosimilars from companies like Amgen and Sandoz. Expected revenue: Significant if approved and marketed broadly.
- AVT04 (ustekinumab biosimilar): Biosimilar to Stelara (ustekinumab), used to treat autoimmune diseases. Competing with Amgen and Teva. Expected to generate revenue depending on the market.
Market Dynamics
Industry Overview
The biosimilars market is growing rapidly due to the expiration of patents on several blockbuster biologics and the increasing demand for affordable medicines.
Positioning
Alvotech is positioned as a key player in the biosimilars market, leveraging its manufacturing capabilities and strategic partnerships. They aim to offer high-quality, cost-effective alternatives to branded biologics.
Total Addressable Market (TAM)
The global biosimilars market is expected to reach hundreds of billions USD. Alvotech is positioned to capture a substantial portion of this TAM through its product pipeline and global partnerships.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Experienced management team
- Strategic partnerships for commercialization
- Focus on complex biosimilars
- Global presence
Weaknesses
- High R&D costs
- Regulatory hurdles
- Competition from established players
- Reliance on partnerships
- Relatively new company compared to larger competitors
Opportunities
- Expanding biosimilars market
- Increasing demand for affordable medicines
- Strategic alliances with larger pharmaceutical companies
- New product development
- Geographic expansion
Threats
- Patent litigation
- Pricing pressures
- Regulatory changes
- Competition from established players
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- AMGN
- SANDOZ (NOVN.SW)
- VTRS
- TEVA
Competitive Landscape
Alvotech competes with large pharmaceutical companies in the biosimilars market. Its strengths lie in its manufacturing capabilities and focus on complex biosimilars. The competitive landscape is challenging due to pricing pressures and patent litigation.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily based on pipeline development and securing partnerships.
Future Projections: Future growth is projected to be driven by regulatory approvals, product launches, and market penetration of its biosimilars.
Recent Initiatives: Recent initiatives include partnerships with Teva Pharmaceuticals and Stada Arzneimittel AG to commercialize its biosimilars worldwide and to continue development of the biosimilar pipeline.
Summary
Alvotech is a growing biosimilar company with strong manufacturing capabilities and strategic partnerships. Their focus on complex biosimilars positions them well in the market, but they face challenges from larger, more established players and regulatory hurdles. The success of their key products and successful partnerships will be crucial for their future growth and profitability. The company has to be mindful of litigation and regulatory challenges.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry News
- SEC Filings of Competitors
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and subject to change. Financial data may be limited due to the company's growth stage.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.